Attached To Antibody Or Antibody Fragment Or Immunoglobulin; Derivative Patents (Class 424/1.49)
  • Patent number: 9050375
    Abstract: This invention relates to bispecific antibodies and antibody fragments against a target protein and a hapten, wherein the hapten is PEG or biotin, most preferably digoxigenin, methods for their production, their use as a delivery platform for therapeutic or diagnostic agents, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Grant
    Filed: June 30, 2010
    Date of Patent: June 9, 2015
    Assignee: Hoffmann-La Roche, Inc.
    Inventors: Birgit Bramlage, Ulrich Brinkmann, Rebecca Croasdale, Simone Dill, Wilma Dormeyer, Guy Georges, Michael Grote, Alexander Haas, Eike Hoffmann, Ludger Markus Ickenstein, Kerstin Jahn-Hofmann, Matthias John, Silke Metz, Olaf Mundigl, Werner Scheuer, Jan Olaf Stracke
  • Patent number: 9050321
    Abstract: The present invention relates to antibodies that are obtained by inserting an amino acid sequence capable of binding to a target into the complementarity determining region (CDR) of a parent antibody. The antibody thus obtained has a new binding specificity. For example, the antibodies of the present invention are able to bind to the target, such as ?v?6 integrin, while retaining one or more of the useful properties of the parent antibody.
    Type: Grant
    Filed: September 26, 2008
    Date of Patent: June 9, 2015
    Assignee: Cancer Research Technology Limited
    Inventors: Kerry Chester, Heide Kogelberg, John F. Marshall
  • Patent number: 9051372
    Abstract: Disclosed are CD70 binding agents, such as anti-CD70 antibodies and derivatives, that induce a cytotoxic, cytostatic or immunosuppressive without conjugation to a therapeutic agents, as well as pharmaceutical compositions and kits comprising the antibody or derivative. Also disclosed are methods for the treatment and prevention of CD70-expressing cancers and immunological disorders comprising administering to a subject the CD70-binding agent.
    Type: Grant
    Filed: November 5, 2008
    Date of Patent: June 9, 2015
    Assignee: Seattle Genetics, Inc.
    Inventors: Che-Leung Law, Julie McEarchern, Alan F. Wahl
  • Publication number: 20150147272
    Abstract: A tissue-targeting complex comprising a tissue targeting moiety, an octadentate hydroxypyridinone-containing ligand comprising four HOPO moieties and the ion of an alpha-emitting thorium radionuclide, where at least one of the four HOPO moieties is substituted at the N-position with a hydroxyalkyi solubilising group and wherein the tissue targeting moiety has binding affinity for the CD33 receptor. A corresponding pharmaceutical formulation and method and use in treatment, as well as methods of manufacture are provided.
    Type: Application
    Filed: May 13, 2013
    Publication date: May 28, 2015
    Inventors: Hanne Therese Bonge-Hanssen, Olav Benjamin Ryan
  • Publication number: 20150147271
    Abstract: Methods are disclosed for diagnosis, prognosis and therapy of acute myeloid leukemia and myelodysplastic syndromes using interleukin 1 receptor accessory protein and other targets.
    Type: Application
    Filed: August 9, 2012
    Publication date: May 28, 2015
    Applicant: Albert Einstein College of Medicine of Yeshiva University
    Inventors: Ulrich G. Steidl, Laura Barreyro De Pujato, Britta Will
  • Patent number: 9040018
    Abstract: Monoclonal antibodies (MoAbs or mAbs) specific for ALPHA-ACTININ-4 antigens, hybridoma lines that secrete these ALPHA-ACTININ-4 mAbs, and the use of such mAbs to detect ALPHA-ACTININ-4 antigens, particularly those expressed by cancer cells are disclosed. Chimeric and humanized antibodies based upon these anti-ALPHA-ACTININ-4 mAbs, processes for producing monoclonal, chimeric, and humanized antibodies using recombinant DNA technology, and their therapeutic uses, particularly in the treatment of cancer are also disclosed. Methods and kits for the immunodetection and immunotherapy of cells for samples which express ALPHA-ACTININ-4 antigens are additionally disclosed.
    Type: Grant
    Filed: December 23, 2011
    Date of Patent: May 26, 2015
    Inventor: Özge Alper
  • Publication number: 20150139899
    Abstract: A method for diagnosing the development of a tissue injury in a subject comprising administering a sample of neoantibodies to the subject's tissue for the purpose of detecting the presence of neoepitopes bearing complement proteins.
    Type: Application
    Filed: January 26, 2015
    Publication date: May 21, 2015
    Inventor: Rekha Bansal
  • Publication number: 20150139900
    Abstract: An in vivo method for detecting ?-synuclein protofibrils in human tissue comprises administering an antibody or fragment thereof to a human, wherein the antibody or fragment thereof is labelled with a detectable label, and detecting a complex formed between the antibody or fragment thereof and ?-synuclein protofibrils in the human tissue. The antibody or fragment thereof has high affinity for human ?-synuclein protofibrils and low binding of ?-synuclein monomers and has a combination of three specified variable heavy (VH) CDR sequences and three specified variable light (VL) CDR sequences.
    Type: Application
    Filed: February 2, 2015
    Publication date: May 21, 2015
    Inventors: Eva Nordström, Alex Kasrayan, Monica Ekberg, Valentina Screpanti Sundquist, Lars Lannfelt, Mats Holmquist
  • Patent number: 9034334
    Abstract: The invention relates to an isolated antibody, or fragment thereof, having high affinity for human A? protofibrils. The invention further relates to compositions that include the antibody, or a fragment thereof, and a pharmaceutically acceptable buffer. The invention further relates to a method of preventing or treating Alzheimer's disease, which includes the step of administering to a patient having or suspected of having Alzheimer's disease such an antibody, or fragment thereof or a composition that includes the antibody or a fragment thereof.
    Type: Grant
    Filed: August 26, 2011
    Date of Patent: May 19, 2015
    Assignee: BioArctic Neuroscience AB
    Inventors: Pär Gellerfors, Lars Lannfelt, Dag Sehlin, Frida Ekholm Pettersson, Hillevi Englund
  • Patent number: 9034254
    Abstract: Disclosed is an antibacterial composition comprising titanium oxide particles immobilized with an antibody having affinity and cognitive power to a microorganism of interest, and a method for sterilizing the microorganism by using the same. In particular, the present invention relates to a method for preparing functional titanium oxide particles capable of recognizing a microorganism or a virus of interest, and a method for selectively and efficiently sterilizing the same by using the functional titanium oxide particles, and not for randomly sterilizing microorganisms or viruses by using conventional titanium oxide particles having no recognition power to a microorganism or a virus of interest.
    Type: Grant
    Filed: November 8, 2012
    Date of Patent: May 19, 2015
    Assignee: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY
    Inventors: Byoung Chan Kim, Jong Soo Jurng, Min Young Song
  • Publication number: 20150132218
    Abstract: The invention provides anti-Ly6E antibodies, immunoconjugates and methods of using the same.
    Type: Application
    Filed: October 20, 2014
    Publication date: May 14, 2015
    Inventors: Jyoti Asundi, Ron Firestein, Paul Polakis, Chie Sakanaka, Peter Chang, Rayna Takaki Venook
  • Patent number: 9029509
    Abstract: The present disclosure relates to binding agents (e.g. antibodies) that bind to and/or modulate the activity of a urokinase plasminogen activator receptor (uPAR/CD87), compositions comprising the antibodies, and methods involving use of the antibodies or compositions.
    Type: Grant
    Filed: February 11, 2011
    Date of Patent: May 12, 2015
    Assignee: The Regents of the University of California
    Inventors: Charles S. Craik, Krishna Sai Duriseti, David H. Goetz
  • Patent number: 9028798
    Abstract: Methods for identifying compounds that modulate the generation of regulatory T cells (Treg) in vivo and in vitro, i.e., compounds that act on the transcription factors that increase or decrease expression of Foxp3.
    Type: Grant
    Filed: January 18, 2013
    Date of Patent: May 12, 2015
    Assignee: The Brigham and Women's Hospital, Inc.
    Inventors: Howard Weiner, Francisco J. Quintana
  • Publication number: 20150125385
    Abstract: The invention relates to variants of an antibody or antigen-binding fragment that binds specifically to an endosialin tumor endothelial marker 1 (TEM1), and prophylactic, diagnostic, and therapeutic methods using the same.
    Type: Application
    Filed: March 15, 2013
    Publication date: May 7, 2015
    Inventors: George Coukos, Chunsheng Li
  • Publication number: 20150125386
    Abstract: The present invention concerns compositions and methods of use of a humanized Class III anti-CEA antibody, comprising the heavy and light amino acid sequences SEQ ID NO:1 and SEQ ID NO:2. The antibody is effective to treat CEACAM5-expressing tumors, either alone or in combination with one or more therapeutic agents. Drug conjugated Class III anti-CEA antibodies, such as SN-38 or P2PDox immunoconjugates, are particularly efficacious. Surprisingly, the antibody-drug conjugates (ADCs) exhibit high anti-cancer efficacy, while exhibiting low levels of systemic toxicity that are readily treated with standard amelioration techniques. Antibodies and/or immunoconjugates comprising the amino acid sequences SEQ ID NO:1 and SEQ ID NO:2 are surprisingly efficacious for therapy of solid tumors, even when the tumor has proven resistant to standard anti-cancer therapies.
    Type: Application
    Filed: October 16, 2014
    Publication date: May 7, 2015
    Inventors: Hans J. Hansen, David M. Goldenberg
  • Publication number: 20150118154
    Abstract: The present invention relates to methods for the treatment, the prognosis and the diagnosis of non-small cell lung cancer.
    Type: Application
    Filed: January 8, 2015
    Publication date: April 30, 2015
    Inventors: Marco Alifano, Patricia Forgez
  • Publication number: 20150118153
    Abstract: The present invention provides affinity matured humanized monoclonal antibodies, bi-specific antibodies, antibody conjugates, and fusion proteins that bind to the chemokine receptor CCR4. This antibody is derived from mAb 1567 and recognizes the same epitope. Binding of the antibodies disclosed herein to CCR4 inhibits ligand-mediated activities and is used to treat symptoms of cancer. Moreover, the antibody is used in combination with vaccines to suppress the activity of regulatory T cells.
    Type: Application
    Filed: May 6, 2013
    Publication date: April 30, 2015
    Inventors: Wayne A. Marasco, Jianhua Sui, Quan Zhu, De-Kuan Chang
  • Publication number: 20150110714
    Abstract: The present invention relates to methods of using the expression of ILTL3 ligand or ILT3 on certain types of cancer cells as a diagnostic tool. Methods are provided for treating ILT3-ligand expressing cancers, such as T-cell acute lymphoblastic leukemia (T-cell acute lymphoblastic leukemia), for example by administering ILT3, the extracellular domain of ILT3 or ILT3Fc conjugated to a cytotoxic agent to kill the targeted cancer cell. Other methods are provided for treating cancers that express ILT3 on their surface, such as monocytic forms of AML, for example by administering anti-ILT3 antibodies conjugated to a cytotoxic agent.
    Type: Application
    Filed: September 4, 2012
    Publication date: April 23, 2015
    Applicant: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
    Inventors: Nicole Suciu-Foca, George Vlad, Chih-Chao Chang, Zhuoru Liu, Adriana Ioana Colovai
  • Patent number: 9012372
    Abstract: The invention relates to the field of biomedical and pharmacological research, in particular to the area of immunology, allergies and autoimmune diseases. The inventors have shown that SWAP-70 is a higher-level regulator for STAT-6 and BCL-6, the regulator being specific for IgE production in B-cells by amplifying the effect of STAT-6 and antagonizing the effect of BCL-6. The inventors have observed no influence of SWAP-70 on the expression of other genes that are likewise regulated by STAT-6 and/or BCL-6. In summary, it can be concluded that SWAP-70 positively regulates IgE production by shifting the interaction of the two antagonists STAT-6 and BCL-6 with regulatory elements of the IgE gene in favor of the activator STAT-6. Based on said findings, the invention provides a screening method which allows for identifying novel active agents that specifically inhibit IgE production.
    Type: Grant
    Filed: April 14, 2011
    Date of Patent: April 21, 2015
    Assignee: Albonia Biotech, Inc.
    Inventors: Rolf Jessberger, Tatsiana Audzevich
  • Publication number: 20150104382
    Abstract: Screening and diagnostic reagents, kits and methods for primary and or metastatic stomach or esophageal cancer are disclosed. Compositions for and methods of imaging and treating primary and/or metastatic stomach or esophageal cancer are disclosed. Vaccines compositions and methods of for treating and preventing primary and/or metastatic stomach for esophageal cancer are disclosed.
    Type: Application
    Filed: October 22, 2014
    Publication date: April 16, 2015
    Inventors: Scott A. Waldman, Jason Park, Stephanie Schulz
  • Publication number: 20150104383
    Abstract: The invention provides methods and compositions employing hybrid molecules of a synthetic molecule and antibody or antibody fragment comprising a selenocysteine residue, wherein the synthetic molecule is covalently linked to the antibody or antibody fragment at the selenocysteine residue. The invention also provides a composition comprising a hybrid molecule as described above and a pharmaceutically acceptable carrier. The invention further provides for methods of making the hybrid molecules, and methods of using the hybrid molecule described above to inhibit cell surface receptor binding.
    Type: Application
    Filed: December 22, 2014
    Publication date: April 16, 2015
    Inventors: Christoph Rader, Thomas Hofer, Terrence R. Burke, JR., Joshua Thomas
  • Patent number: 9005574
    Abstract: The invention relates to (glyco-) proteins, in particular monoclonal antibodies, which have an immunoreactivity of >81%, preferably >90%. The inventive monoclonal antibodies are produced using a fluidized bed reactor in conjunction with a conventional protein-chemical purification method or preferably with a purification method involving less column chromatography. The monoclonal antibodies thus produced are suitable, in gamma-irradiated form, e.g. Tc-99m labeled, for the in vivo diagnosis of inflammatory diseases and bone marrow metastases. In alpha- or beta-irradiated form, e.g. astatine or Re-188 or Y-90 labeled form, the inventive monoclonal antibodies can be used, for example, in the treatment of leukemia.
    Type: Grant
    Filed: September 16, 2010
    Date of Patent: April 14, 2015
    Assignee: Scintec Diagnostics
    Inventors: Ivan Benes, Silke Thomsen-Bosslet
  • Publication number: 20150098900
    Abstract: The invention provides anti-FcRH5 antibodies and immunoconjugates and methods of using the same.
    Type: Application
    Filed: June 24, 2014
    Publication date: April 9, 2015
    Inventors: Allen J. Ebens, Meredith C. Hazen, Jo-Anne Hongo, Jennifer W. Johnston, Teemu T. Junttila, Ji Li, Andrew G. Polson
  • Publication number: 20150098901
    Abstract: The present invention is directed to improved methods for generating compositions comprising actinium-225.
    Type: Application
    Filed: October 6, 2014
    Publication date: April 9, 2015
    Inventors: Eva Rachel Birnbaum, Jonathan W. Engle, Francois Meiring Nortier
  • Patent number: 8999289
    Abstract: The invention relates to methods of treating protein degradation disorders, such cellular proliferative disorders (e.g., cancer) and protein deposition disorders (e.g., neurodegenerative disorders). The invention provides methods and pharmaceutical compositions for treating these diseases using aggresome inhibitors or combinations of aggresome inhibitors and proteasome inhibitors. The invention further relates to methods and pharmaceutical compositions for treating multiple myeloma. New HDAC/TDAC inhibitors and aggresome inhibitors are also provided as well as synthetic methodologies for preparing these compounds.
    Type: Grant
    Filed: March 22, 2006
    Date of Patent: April 7, 2015
    Assignees: President and Fellows of Harvard College, Dana-Farber Cancer Institute, Inc.
    Inventors: Kenneth C. Anderson, James E. Bradner, Edward Franklin Greenberg, Teru Hideshima, Nicholas Paul Kwiatkowski, Ralph Mazitschek, Stuart L. Schreiber, Jared Shaw, Stephen J. Haggarty
  • Publication number: 20150086478
    Abstract: The invention relates to humanized recombinant antibodies targeting the EGFR family receptors EGFR, HER2 and HER3, compositions comprising at least one humanized anti-EGFR antibody, at least one humanized anti-HER2 antibody and at least one humanized anti-HER3 antibody, and use of the antibody compositions for treatment of cancer. The invention also relates to the use of antibodies targeting multiple EGFR-family receptors to treat cancer (e.g., pancreatic cancer) and cancer that has acquired resistance to previous therapies.
    Type: Application
    Filed: May 2, 2013
    Publication date: March 26, 2015
    Inventors: Johan Lantto, Kim Vilbour Andersen, Peter Sejr Andersen, Magnus Strandh, Klaus Koefoed, Lars Søgaard Nielsen, Mikkel Wandahl Pedersen, Helle Jacobsen, Michael Kragh, Ida Kjær, Thomas Tuxen Poulsen
  • Publication number: 20150078996
    Abstract: The present invention relates to mammalian antibodies, designated 12B1 and antigen-binding portions thereof that specifically bind to insulin-like growth factor I receptor (IGF-IR), preferably human IGF-IR. Also included are chimeric, bispecific, derivatized, single chain antibodies derived from the antibodies disclosed herein. Nucleic acid molecules encoding the mammalian antibodies as well as methods of use thereof are also disclosed. Also included are pharmaceutical compositions comprising these antibodies and methods of using the antibodies and compositions thereof for treatment and diagnosis of pathological hyperproliferative oncogenic disorders associated with expression of IGf-1R.
    Type: Application
    Filed: September 19, 2014
    Publication date: March 19, 2015
    Inventors: Liliane Goetsch, David Brooks, Michael Chastain, Zhi-Qiang Zhang, Nathalie Corvaia
  • Publication number: 20150078995
    Abstract: A nanotheranostic probe and its use to facilitate diagnoses, treatment and targeting of amyloid deposits are disclosed herein.
    Type: Application
    Filed: September 16, 2014
    Publication date: March 19, 2015
    Inventor: Karunya K. Kandimalla
  • Publication number: 20150071854
    Abstract: The present invention relates to monoclonal antibodies that bind or neutralize Hendra or Nipah virus. The invention provides such antibodies, fragments of such antibodies retaining Hendra or Nipah virus-binding ability, fully human antibodies retaining Hendra or Nipah virus-binding ability, and pharmaceutical compositions including such antibodies. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. Additionally, the invention provides for prophylactic, therapeutic, and diagnostic methods employing the antibodies and nucleic acids of the invention.
    Type: Application
    Filed: September 18, 2014
    Publication date: March 12, 2015
    Inventors: Dimiter S. Dimitrov, Zhongyu Zhu, Christopher C. Broder
  • Publication number: 20150056135
    Abstract: Methods of treating cancer in a patient are provided. In some embodiments the method comprises administering an antibody that is capable of binding to the extracellular domain of PSMA after first administering a hormonal therapy.
    Type: Application
    Filed: November 10, 2014
    Publication date: February 26, 2015
    Inventor: Neil H. Bander
  • Publication number: 20150056134
    Abstract: The present invention provides compositions for the production of an antibody or functional fragment thereof directed against Sialyl-Lewisa (sLea). The compositions of the invention include polynucleotides encoding a heavy chain and/or a light chain variable domain that binds to sLea. The invention also provides an isolated antibody or functional fragment thereof and methods of treating or preventing a disease, such as cancer or tumor formation, wherein the antibody or functional fragment includes a variable heavy chain domain and a variable light chain domain that has an amino acid sequence provided herein. The invention further provides a conjugate of an antibody or functional fragment thereof conjugated or recombinantly fused to a diagnostic agent, detectable agent or therapeutic agent, and methods of treating, preventing or diagnosing a disease in a subject in need thereof.
    Type: Application
    Filed: August 26, 2014
    Publication date: February 26, 2015
    Inventors: Ritsuko SAWADA, Shu-Man SUN, Wolfgang SCHOLZ
  • Publication number: 20150056133
    Abstract: The present invention relates to CX3CR1-targeting imaging agents and their use in treatment and diagnosis of diseases. Single domain CX3CR1-targeting polypeptides linked to detection labels and their use in in vivo imaging of atherosclerotic plaques are described. The CX3CR1-targeting imaging agents are useful in the treatment and diagnosis of CX3CR1-mediated diseases including atherosclerosis.
    Type: Application
    Filed: August 20, 2014
    Publication date: February 26, 2015
    Inventors: Alisa K. WATERMAN, Nick Mark Devoogdt, Tony Lahoutte, Matthias SCHNEIDER, Sanjaya SINGH, Cedric Jozef Néotère VERVERKEN
  • Publication number: 20150056132
    Abstract: Anti-STEAP-1 antibodies and immunoconjugates thereof are provided. Methods of using anti-STEAP-1 antibodies and immunoconjugates thereof are provided. Methods of detecting or determining the presence of STEAP-1 proteins are provided.
    Type: Application
    Filed: May 27, 2014
    Publication date: February 26, 2015
    Applicant: Genentech, Inc.
    Inventors: Mark DENNIS, Jan Marik, Paul Polakis, Bonnee Rubinfeld, Simon Williams
  • Patent number: 8961968
    Abstract: Isolated human monoclonal antibodies which bind to and inhibit human CD25, and related antibody-based compositions and molecules, are disclosed. The human antibodies can be produced by a hybridoma, a transfectoma or in a nonhuman transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, nonhuman transgenic animals, hybridomas and transfectomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.
    Type: Grant
    Filed: May 7, 2012
    Date of Patent: February 24, 2015
    Assignee: Genmab A/S
    Inventors: Janine Schuurman, Catharina Emanuele Gerarda Havenith, Paul Parren, Jan G. J. Van De Winkel, Denise Leah Williams, Jørgen Petersen, Ole Baadsgaard
  • Publication number: 20150044135
    Abstract: The invention described herein relates to the detection, diagnosis, and treatment of intestinal metaplasias that develop to esophageal, gastric, and pancreatic adenocarcinoma. The stem cells and differentiated cells of these intestinal metaplasias show high expression of CDH17 as well as other proteins. The invention also includes a clonal population of Barrett's esophagus stem cells as well as the stem cells of the surrounding normal epithelia and methods of using them for the detection, diagnosis, and treatment of Barrett's esophagus.
    Type: Application
    Filed: September 24, 2014
    Publication date: February 12, 2015
    Inventors: Wa Xian, Frank McKeon, Matthew Vincent, Khek Yu Ho
  • Patent number: 8951499
    Abstract: A reagent for conjugation to a biomolecule, wherein the reagent is a single molecule with at least three functional parts and has schematic structure (I): a) wherein a trifunctional cross-linking moiety is coupled to b) an affinity ligand via a linker 1, said affinity ligand being capable of binding with another molecule having affinity for said ligand, to c) an effector agent, optionally via a linker 2, said effector agent exerting its effect on cells, tissues and/or humorous molecules in vivo or ex vivo, and to d) a biomolecule reactive moiety, optionally via a linker 3, said moiety being capable of forming a bond between the reagent and the biomolecule.
    Type: Grant
    Filed: September 6, 2006
    Date of Patent: February 10, 2015
    Assignees: University of Washington, Glycorex Transplantation AB
    Inventors: D. Scott Wilbur, Bengt E. B. Sandberg
  • Publication number: 20150037251
    Abstract: The invention relates inhibiting nucleic acids directed at mammalian homologues of the Drosophila fwe gene (Flower) and to antibodies against the respective proteins, and their use in diagnosing, preventing and treating cancer.
    Type: Application
    Filed: February 18, 2013
    Publication date: February 5, 2015
    Applicants: UNIVERSITAT BERN, CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS
    Inventors: Christa Rhiner, Evgeniya Pertova, Jesus M. Lopez-Gay, Eduardo Moreno
  • Publication number: 20150030533
    Abstract: Disclosed are methods and compositions for the detection, diagnosis, prognosis, and therapy of hematological malignancies, and in particular, B cell leukemias, lymphomas and multiple myelomas. Disclosed are compositions, methods and kits for eliciting immune and T cell responses to specific malignancy-related antigenic polypeptides and antigenic polypeptide fragments thereof in an animal. Also disclosed are compositions and methods for use in the identification of cells and biological samples containing one or more hematological malignancy-related compositions, and methods for the detection and diagnosis of such diseases and affected cell types. Also disclosed are diagnostic and therapeutic kits, as well as methods for the diagnosis, therapy and/or prevention of a variety of leukemias and lymphomas.
    Type: Application
    Filed: June 6, 2014
    Publication date: January 29, 2015
    Inventors: Paul A. Algate, Lauren Carter, Johathan David Clapper, Alexander Gaiger, Jane Mannion, Patricia Dianne McNeill, Nadia Ordonez, Aijun Wang
  • Publication number: 20150030535
    Abstract: Antibodies and meditopes that bind to the antibodies are provided, as well as complexes, compositions and combinations containing the meditopes and antibodies, and methods of producing, using, testing, and screening the same, including therapeutic and diagnostic methods and uses.
    Type: Application
    Filed: August 6, 2014
    Publication date: January 29, 2015
    Inventors: John C. WILLIAMS, David A. HORNE, Yuelong MA, Heng Wei CHANG, Joshua M. DONALDSON, Cindy ZER, Krzysztof BZYMEK, Kendra N. AVERY, Jun XIE
  • Publication number: 20150030536
    Abstract: The invention relates to a binding member that binds the Extra Domain-A (ED-A) isoform of fibronectin for the treatment of lung cancer and lymphoma.
    Type: Application
    Filed: August 11, 2014
    Publication date: January 29, 2015
    Inventors: Dario Neri, Alessandra Villa, Eveline Trachsel, Jascha-Nikolai Rybak
  • Publication number: 20150030534
    Abstract: The present invention provides compositions comprising a therapeutically effective combination of at least two of radionuclide-labeled anti-Epidermal Growth Factor Receptor (anti-EGFR), radionuclide-labeled anti-CD-44, and radionuclide-labeled anti-CD-73. or their respective antigen binding portions, and a pharmaceutically acceptable carrier, and method of use thereof for the treatment of breast cancer.
    Type: Application
    Filed: July 28, 2014
    Publication date: January 29, 2015
    Inventors: Roger W. Howell, John M. Akudugu, Jordan B. Pasternack
  • Patent number: 8940272
    Abstract: Provided are novel human tau-specific antibodies as well as fragments, derivatives and variants thereof as well as methods related thereto. Assays, kits, and solid supports related to antibodies specific for tau are also disclosed. The antibody, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for tau targeted immunotherapy and diagnosis, respectively.
    Type: Grant
    Filed: October 11, 2011
    Date of Patent: January 27, 2015
    Assignees: University of Zurich, Biogen Idec International Neuroscience GmbH
    Inventors: Roger Nitsch, Feng Chen, Jan Grimm, Jean-Luc Baeriswyl, Christoph Hock
  • Publication number: 20150023870
    Abstract: Disclosed herein are compositions and methods of use comprising hexavalent DNL complexes. Preferably, the complexes comprise anti-CD20 and/or anti-CD22 antibodies or fragments thereof. More preferably, the anti-CD20 antibody is veltuzumab and the anti-CD22 antibody is epratuzumab. Administration of the subject hexavalent DNL complexes induces apoptosis and cell death of target cells in diseases such as B-cell lymphomas or leukemias, autoimmune disease or immune dysfunction disease. In most preferred embodiments, the DNL complexes increase levels of phosphorylated p38 and PTEN, decrease levels of phosphorylated Lyn, Akt, ERK, IKK?/? and I?B?, increase expression of RKIP and Bax and decrease expression of Mcl-1, Bcl-xL, Bcl-2, and phospho-BAD in target cells. The subject DNL complexes show EC50 values for inhibiting tumor cell growth in the low nanomolar or even sub-nanomolar concentration range.
    Type: Application
    Filed: September 19, 2014
    Publication date: January 22, 2015
    Applicant: IBC PHARMACEUTICALS, INC.
    Inventors: Chien-Hsing Chang, David M. Goldenberg, Edmund A. Rossi
  • Publication number: 20150017094
    Abstract: Antibodies are engineered by replacing one or more amino acids of a parent antibody with non cross-linked, highly reactive cysteine amino acids. Antibody fragments may also be engineered with one or more cysteine amino acids to form cysteine engineered antibody fragments (ThioFab). Methods of design, preparation, screening, and selection of the cysteine engineered antibodies are provided. Cysteine engineered antibodies (Ab) are conjugated with one or more zirconium complex (Z) labels through a linker (L) to form cysteine engineered zirconium-labeled antibody conjugates having Formula I: Ab-(L-Z)p??I where p is 1 to 4. Imaging methods and diagnostic uses for zirconium-radiolabeled, cysteine engineered antibody conjugate compositions are disclosed.
    Type: Application
    Filed: June 10, 2014
    Publication date: January 15, 2015
    Inventors: Herman Gill, Jagath R. Junutula, Henry B. Lowman, Jan Marik, Jeff Tinianow, Simon Williams
  • Publication number: 20150017096
    Abstract: The present invention relates to the use of an inhibitor of HER-3 for the treatment of a hyperproliferative disease in combination with radiation treatment.
    Type: Application
    Filed: February 22, 2013
    Publication date: January 15, 2015
    Inventors: Deric L. Wheeler, Thore Hettmann
  • Publication number: 20150017095
    Abstract: The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.
    Type: Application
    Filed: July 9, 2014
    Publication date: January 15, 2015
    Inventors: Tariq Ghayur, Jijie Gu, Peter Isakson
  • Patent number: 8932593
    Abstract: The present invention concerns methods and compositions for stably tethered structures of defined compositions, which may have multiple functionalities and/or binding specificities. Particular embodiments concern homodimers comprising monomers that contain a dimerization and docking domain attached to a precursor. The precursors may be virtually any molecule or structure, such as antibodies, antibody fragments, antibody analogs or mimetics, aptamers, binding peptides, fragments of binding proteins, known ligands for proteins or other molecules, enzymes, detectable labels or tags, therapeutic agents, toxins, pharmaceuticals, cytokines, interleukins, interferons, radioisotopes, proteins, peptides, peptide mimetics, polynucleotides, RNAi, oligosaccharides, natural or synthetic polymeric substances, nanoparticles, quantum dots, organic or inorganic compounds, etc. Other embodiments concern tetramers comprising a first and second homodimer, which may be identical or different.
    Type: Grant
    Filed: March 14, 2012
    Date of Patent: January 13, 2015
    Assignee: IBC Pharmaceuticals, Inc.
    Inventors: Chien-Hsing Chang, David M. Goldenberg, William J. McBride, Edmund A. Rossi
  • Patent number: 8920776
    Abstract: Disclosed are methods and compositions for the detection, diagnosis, prognosis, and therapy of hematological malignancies, and in particular, B cell leukemias, lymphomas and multiple myelomas. Disclosed are compositions, methods and kits for eliciting immune and T cell responses to specific malignancy-related antigenic polypeptides and antigenic polypeptide fragments thereof in an animal. Also disclosed are compositions and methods for use in the identification of cells and biological samples containing one or more hematological malignancy-related compositions, and methods for the detection and diagnosis of such diseases and affected cell types. Also disclosed are diagnostic and therapeutic kits, as well as methods for the diagnosis, therapy and/or prevention of variety of leukemias and lymphomas.
    Type: Grant
    Filed: January 22, 2003
    Date of Patent: December 30, 2014
    Assignee: Corixa Corporation
    Inventors: Alexander Gaiger, Paul A. Algate, Jane Mannion, Jonathan David Clapper, Aijun Wang, Nadia Ordonez, Lauren Carter, Patricia Dianne McNeill
  • Publication number: 20140377173
    Abstract: Described herein are compositions and methods of use of anti-pancreatic cancer antibodies or fragments thereof, such as murine, chimeric, humanized or human PAM4 antibodies. The antibodies show novel and useful diagnostic characteristics, such as binding with high specificity to pancreatic and other cancers, but not to normal or benign pancreatic tissues and binding to a high percentage of early stage pancreatic cancers. Preferably, the antibodies bind to pancreatic cancer mucins such as MUC1 or MUC5ac and are of use for the detection and diagnosis of early stage pancreatic cancer. In more preferred embodiments, the anti-pancreatic cancer antibodies can be used for immunoassay of serum samples, wherein the immunoassay detects a marker for early stage pancreatic cancer in serum. Most preferably, the serum is extracted with an organic phase, such as butanol, before immunoassay. Alternatively, immunoassay with PAM4 and anti-CA19.9 antibodies may be utilized to improve sensitivity for pancreatic cancer.
    Type: Application
    Filed: June 24, 2014
    Publication date: December 25, 2014
    Inventors: David V. Gold, David M. Goldenberg
  • Publication number: 20140377172
    Abstract: The subject invention pertains to antibodies that have binding specificity for an antigen that is expressed on a subset of human, hematopoietic mononuclear cells, including a hematopoietic stem cell population, but is not expressed on normal, mature myeloid cells. In one embodiment, a monoclonal antibody, MG1, is provided. This antibody is useful in methods of isolating cell suspensions from human blood and marrow that can be employed in bone marrow transplantation, genetic therapy, and in treating other diseases of the hematopoietic system. Cell suspensions containing MG1+ human hematopoietic cells are also provided, as well as therapeutic methods employing the cell suspensions. The subject invention also pertains to the novel antigen recognized by the subject antibodies.
    Type: Application
    Filed: March 4, 2010
    Publication date: December 25, 2014
    Applicant: Morphogenesis, Inc.
    Inventors: Michael J.P. Lawman, Patricia Lawman